Suzy Dilly, ValiRx CEO reiterates her support for TheoremRx and hails 'brilliant science' Cytolytix
Suzy Dilly, CEO at the early stage cancer therapeutics business ValiRx ( VAL ) joined London South East to tell us about Cytolytix, the 60% owned subsidiary created to deal with an exciting new...